Severe motor neuron degeneration in the spinal cord of the Tg2576 mouse model of Alzheimer disease

Journal of Alzheimer's Disease

Volumn 21, Issue 1, 2010, Pages 263-276

  Seo, Ji Seon ^a   Leem, Yea Hyun ^a   Lee, Kang Woo ^a   Kim, Seung Woo ^b   Lee, Ja Kyeong ^b   Han, Pyung Lim ^a  

^a Ewha Womans University   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Motor neurons; reactive oxygen species; spinal cord; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; AMYLOID PRECURSOR PROTEIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CYANIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIPID STORAGE; MALE; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SPINAL CORD ATROPHY; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HINDLIMB; HUMAN; METABOLISM; MITOCHONDRION; MOTONEURON; MOVEMENT DISORDERS; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REFLEX; SPINAL CORD; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; TREMOR; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINERGIC AGENTS; CURCUMIN; DISEASE MODELS, ANIMAL; HINDLIMB; HUMANS; LIPID PEROXIDATION; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; MOTOR NEURONS; MOVEMENT DISORDERS; NERVE DEGENERATION; POTASSIUM CYANIDE; REFLEX; SPINAL CORD; TREMOR;

EID: 77954978168     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091528     Document Type: Article

References (41)

1. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
2. Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, Brunden KR (1999) Evidence for glial-mediated inflammation in aged APPsw transgenic mice. Neurobiol Aging 20, 581-589.
3. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381.
4. King DL, Arendash GW (2002) Behavioral characterization of the Tg2576 transgenic model Alzheimer's disease through 19 months. Physiol Behavior 75, 627-642.
5. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144.
6. Prusiner SB (1991) Molecular biology of prion diseases. Science 252, 1515-1552.
7. Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, Ho H, Brady ST, Sisodia SS (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27, 7011-7020.
8. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA (2006) Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol 111, 312-319.
9. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA (2007) Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 28, 1689-1699.
10. Lee KW, Kim JB, Seo JS, Kim TK, Im JY, Baek IS, Kim KS, Lee JK, Han PL (2009) Behavioral stress accelerates plaque pathogenesis in the brain of Tg2 576 mice via generation of metabolic oxidative stress. JNeurochem 108, 165-175.
11. Seo JS, Kim TK, Leem YH, Lee KW, Park SK, Baek IS, Kim KS, Im GJ, Lee SM, Park YH, Han PL (2009) SK-PC-B70M confers anti-oxidant activity and reduces Aft levels in the brain of Tg2576 mice. Brain Res 1261, 100-108.
12. Im JY, Kim D, Paik SG, Han PL (2006) Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radic Biol Med 41, 960-972.
13. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, Munnich A (1994) Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 228, 35-51.
14. Janssen AJ, Trijbels FJ, Sengers RC, Smeitink JA, van den Heuvel LP, Wintjes LT, Stoltenborg-Hogenkamp BJ, Roden-burg RJ (2007) Spectrophotometric assay for complex I ofthe respiratory chain in tissue samples and cultured fibroblasts. Clin Chem 53, 729-734.
15. Siu PM, Donley DA, Bryner RW, Alway SE (2003) Citrate syn-thase expression and enzyme activity after endurance training in cardiac and skeletal muscles. J Appl Physiol 94, 555-560.
16. Barneoud P, Lolivier J, Sanger DJ, Scatton B, Moser P (1997) Quantitative motor assessment in FALS mice: a longitudinal study. Neuro Report 8, 2861-2865.
17. Weydt P, Hong SY, Kliot M, Moller T (2003) Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuro Report 14, 1051-1054.
18. Norreel JC, Jamon M, Riviere G, Passage E, Fontes M, Clarac F (2001) Behavioural profiling of a murine Charcot-Marie-Tooth disease type 1A model. Eur J Neurosci 13, 1625-1634.
19. Lee KW, Im JY, Song JS, Lee SH, Lee HJ, Ha HY, Koh JY, Gwag BJ, Yang SD, Paik SG, Han PL (2006) Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. Neurobiol Dis 22, 10-24
20. Barnes P, Good M (2005) Impaired Pavlovian cued fear conditioning in Tg2576 mice expressing a human mutant amyloid precursor protein gene. Behav Brain Res 157, 107-117.
21. Frank B, Gupta S (2005) A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 17, 269-286
22. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377.
23. Gil-Bea FJ, Aisa B, Schliebs R, Ramirez MJ (2007) Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. Behav Neurosci 121, 340-344.
24. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, Dubois B, Sarazin M, Brandt J, Albert M, Marder K, Bell K, Honig LS, Wegesin D, Stern Y (2004) Motor signs during the course of Alzheimer disease. Neurology 63, 975-982.
25. Yagishita S (1978) Morphological investigations on axonal swellings and spheroids in various human diseases. Virchows Arch A Pathol AnatHistol 378, 181-197.
26. Weis J, Saxena S, Evangelopoulos ME, Kruttgen A (2003) Trophic factors in neurodegenerative disorders. IUBMB Life 55, 353-357.
27. Roy S, Zhang B, Lee VM, Trojanowski JQ (2005) Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol 109, 5-13.
28. Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurode-generation in Alzheimer's disease brain. A review. Free Radic Res 36, 1307-1313.
29. Butterfield DA, Boyd-Kimball D (2004) Amyloid ft-peptide (1-42) contributes to the oxidative stress and neurodegenera-tion found in Alzheimer's disease. Brain Pathol 14, 426-432.
30. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY (2008) Amyloid beta pep-tide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106, 45-55.
31. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100, 10417-10422.
32. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid ft oligomers. J Neurosci 24, 10191-10200.
33. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neu-rodegeneration: lessons from the Alzheimer's amyloid beta-peptide. NatRevMol Cell Biol 8, 101-112.
34. Chaturvedi RK, Beal MF (2008) Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 1147, 395-412.
35. Rhein V, Baysang G, Rao S, Meier F, Bonert A, Muller-Spahn F, Eckert A (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29, 1063-1071.
36. Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly Jr ES, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE (2005) Physicochemi-cal characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res 27, 869-881.
37. Wijesekera LC, Leigh PN (2009) Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4, 3.
38. Radunovic A, Leigh PN (1996) Cu/Zn superoxide dismu-tasegene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neuro-surg Psychiatry 61, 565-572.
39. Pasinelli P, and Brown RH (2006) Molecular biology of amy-otrophic lateral sclerosis: insights from genetics. Nat Rev Neu-rosci 7, 710-723.
40. Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595, 197-212.
41. Hamaguchi T, Ono K, Murase A, Yamada M. (2009) Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175, 2557-2565.